Curis, Inc. (CRIS)

Market Cap	19.36M
Revenue (ttm)	11.20M
Net Income (ttm)	-42.13M
Shares Out	10.46M
EPS (ttm)	-6.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	168,578
Open	1.730
Previous Close	1.740
Day's Range	1.690 - 1.899
52-Week Range	1.020 - 8.290
Beta	3.60
Analysts	Strong Buy
Price Target	16.50 (+791.89%)
Earnings Date	Jul 31, 2025

About CRIS

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with r...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 1, 2000
• Employees: 34
• Stock Exchange: NASDAQ
• Ticker Symbol: CRIS
• Website: https://www.curis.com

Financial Performance

In 2024, Curis's revenue was $10.91 million, an increase of 8.83% compared to the previous year's $10.02 million. Losses were -$43.39 million, -8.49% less than in 2023.

Analyst Summary

According to 2 analysts, the average rating for CRIS stock is "Strong Buy." The 12-month stock price target is $16.5, which is an increase of 791.89% from the latest price.

Price Target

$16.5

(791.89% upside)

Analyst Consensus: Strong Buy